BioLife Solutions Inc. is a U.S.-based life sciences company focused on bioproduction tools and services for the cell and gene therapy industry. It develops, manufactures, and markets products designed to preserve the health and function of biologic material during sourcing, manufacturing, storage, and transport. The company’s portfolio centers on biopreservation media, cell processing products, and automated thawing and handling devices used in research and commercial manufacturing. BioLife has also used acquisitions and divestitures to sharpen its focus on the core bioproduction workflow. Its business model is tied to the growth of commercial cell and gene therapies, where product reliability and handling quality are critical.
−14,9 %
64,6 %
−4,8 %
+28,9 %
5.94
4.63
| % | |
|---|---|
| Biopreservation media | 55% Specialized media used to maintain viability and function of biologic material during sourcing, processing, storage, and transport. |
| Cell processing products | 20% Tools such as hPL media, cryogenic containers, and fill machines used in cell handling and manufacturing workflows. |
| Automated thawing devices | 10% ThawSTAR devices and related systems that standardize thawing of biologic materials before use. |
| Shipping and temperature-control solutions | 10% Smart shipping containers and cold-chain products used to protect biologic materials in transit. |
| Services and technical support | 5% Application support, customer care, and technical services that help customers implement and use the products. |
BioLife sells primarily to cell and gene therapy developers, biopharma manufacturers, and research organizations that...
Buy biopreservation media and processing tools to protect cells during development, scale-up, and clinical manufacturing.
Purchase recurring consumables and workflow products to support approved therapies and commercial production.
Use the company’s media and handling products for basic and translational research involving biologic materials.
Resell the company’s products in regional markets and help extend commercial reach without direct local infrastructure.
BioLife is headquartered in Bothell, Washington and operates as a U.S.-based company with sales to customers located by...
BioLife’s strategy is to concentrate on the bioproduction workflow for cell and gene therapy and expand the value of...
The company’s competitive position depends on being embedded in the customer’s biologic manufacturing process.
New products can increase wallet share and improve customer retention in a specialized market.
Adjacencies can extend the platform and add capabilities without building everything internally.
Customers buy based on performance, application fit, and support quality, not just product specs.
BioLife faces product-performance and technology-risk exposure because its products are used in sensitive biologic...
Customers rely on the products to preserve biologic material, so defects or doubts about performance can directly reduce sales and trust.
The company’s demand is linked to cell and gene therapy spending, which can fluctuate with funding conditions and destocking.
Failures in products used in biologic manufacturing can create claims, remediation costs, and reputational damage.
Facility shutdowns or component shortages can delay shipments and reduce revenue recognition timing.
Pandemics or epidemics can affect workforce availability, logistics, and customer access.
The business depends on scientific, engineering, and sales expertise to support customers and develop products.
: 11/08/2026